Andrew Ko, MD
Data presented at the 2018 Gastrointestinal Cancers Symposium showcased the efficacy of targeted agents and immunotherapy in select settings of gastric/gastroesophageal junction (GEJ) cancers, yet ongoing studies could further define the role of immunotherapy, explained Andrew Ko, MD.
State of the Science Summit™ on Gastrointestinal Cancers, Ko, professor in the Department of Medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discussed how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.
OncLive: What highlights have we seen in the past year in gastric/GEJ cancers?
There are a number of developments that have been practice changing. In terms of novel therapies, the approval of pembrolizumab in the fall of 2017 has changed the way we treat advanced disease. This is specific to the subset of patients with gastric/GEJ cancers with positive PD-L1 expression. There is biomarker selection criteria we use as a basis for which drugs can and should be used.
... to read the full story